✦ LIBER ✦

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

✍ Scribed by Costa, C.; Molina, M. A.; Drozdowskyj, A.; Gimenez-Capitan, A.; Bertran-Alamillo, J.; Karachaliou, N.; Gervais, R.; Massuti, B.; Wei, J.; Moran, T.; Majem, M.; Felip, E.; Carcereny, E.; Garcia-Campelo, R.; Viteri, S.; Taron, M.; Ono, M.; Giannikopoulos, P.; Bivona, T.; Rosell, R.

Book ID: 121495429
Publisher: American Association for Cancer Research
Year: 2014
Tongue: English
Weight: 651 KB
Volume: 20
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.CCR-13-2233

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9017 POSTER DISCUSSION Initial Detection

9017 POSTER DISCUSSION Initial Detection of the Double Epidermal Growth Factor Receptor (EGFR) Mutation (L858R or Deletion in Exon 19 [del 19] Plus T790M) in Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Brain Metastases (mets) and the Influence of First-Line Chemotherapy on Outcome to Erlotinib

✍ Rolfo, C.; Moran, T.; Sanchez, J.; Molina-Vila, M.; Bertran-Alamilllo, J.; Camps 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB